TY - JOUR
T1 - A French retrospective study on clinical outcome in 102 choroid plexus tumors in children
AU - Siegfried, A.
AU - Morin, S.
AU - Munzer, C.
AU - Delisle, M. B.
AU - Gambart, M.
AU - Puget, S.
AU - Maurage, C. A.
AU - Miquel, C.
AU - Dufour, C.
AU - Leblond, P.
AU - André, N.
AU - Branger, D. Figarella
AU - Kanold, J.
AU - Kemeny, J. L.
AU - Icher, C.
AU - Vital, A.
AU - Coste, E. Uro
AU - Bertozzi, A. I.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - The aim of this study was to review and describe therapeutic approaches in children with choroid plexus tumor (CPT) based on a nationwide series. The World Health Organization classification subdivides these rare tumors into three histological subtypes corresponding to three grades of malignancy: low grade (grade I) choroid plexus papilloma (CPP), intermediate grade (grade II) atypical choroid plexus papilloma (aCPP) and high grade (grade III) choroid plexus carcinoma (CPC). This retrospective study included 102 French children younger than 18 years, treated from 2000 to 2012: 54 CPP, 26 aCPP and 22 CPC. The 5 year overall survival was 100% in CPP, 96.2% in aCPP and 64.7% in CPC. In patients with localized disease, complete surgical resection was achieved in 48/52 CPP, 20/26 aCPP and 7/14 CPC. In this group, patients with complete surgical resection had better event free survival than patients with partial resection (88.9 vs. 41.6%). 28 patients (1 CPP, 6 aCPP and 22 CPC) had adjuvant chemotherapy. 2 aCPP and 9 CPC had radiotherapy. We underlined the need for a central histological review to accurately analyze clinical data; we reported a much higher overall survival for CPC than in most previous CPT series probably including atypical teratoid rhabdoid tumors. In our series, the 5 years overall survival in CPC (64.7%) was higher than event free survival (25.2%) and could be interpreted as a clue for the efficiency of adjuvant/salvage therapy even if the heterogeneity of applied treatments in this retrospective series does not allow for meaningful statistical comparisons.
AB - The aim of this study was to review and describe therapeutic approaches in children with choroid plexus tumor (CPT) based on a nationwide series. The World Health Organization classification subdivides these rare tumors into three histological subtypes corresponding to three grades of malignancy: low grade (grade I) choroid plexus papilloma (CPP), intermediate grade (grade II) atypical choroid plexus papilloma (aCPP) and high grade (grade III) choroid plexus carcinoma (CPC). This retrospective study included 102 French children younger than 18 years, treated from 2000 to 2012: 54 CPP, 26 aCPP and 22 CPC. The 5 year overall survival was 100% in CPP, 96.2% in aCPP and 64.7% in CPC. In patients with localized disease, complete surgical resection was achieved in 48/52 CPP, 20/26 aCPP and 7/14 CPC. In this group, patients with complete surgical resection had better event free survival than patients with partial resection (88.9 vs. 41.6%). 28 patients (1 CPP, 6 aCPP and 22 CPC) had adjuvant chemotherapy. 2 aCPP and 9 CPC had radiotherapy. We underlined the need for a central histological review to accurately analyze clinical data; we reported a much higher overall survival for CPC than in most previous CPT series probably including atypical teratoid rhabdoid tumors. In our series, the 5 years overall survival in CPC (64.7%) was higher than event free survival (25.2%) and could be interpreted as a clue for the efficiency of adjuvant/salvage therapy even if the heterogeneity of applied treatments in this retrospective series does not allow for meaningful statistical comparisons.
KW - Atypical choroid plexus papilloma
KW - Atypical teratoid rhabdoid tumor
KW - Chemotherapy
KW - Choroid plexus carcinoma
KW - Choroid plexus papilloma
KW - Choroid plexus tumor
UR - http://www.scopus.com/inward/record.url?scp=85021793994&partnerID=8YFLogxK
U2 - 10.1007/s11060-017-2561-2
DO - 10.1007/s11060-017-2561-2
M3 - Article
C2 - 28677107
AN - SCOPUS:85021793994
SN - 0167-594X
VL - 135
SP - 151
EP - 160
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 1
ER -